Traditional Chinese medicine (TCM) has more than 2,000 years of history and has gained widespread clinical applications.
RCTs on TCM have had small sample sizes, used surrogate endpoints, followed study patients for a short period of time, and reported diverse outcomes.
Here, we aim to critically evaluate the beneficial and detrimental effects of TCM in patients with CVD, as well as the underlying mechanisms. We searched for the most up-to-date (the past 10 years) published studies of RCTs using pre-defined, strict inclusion and exclusion criteria, and systemically assessed the efficacy and safety of TCM therapy for patients with CVD risk factors (hypertension, dyslipidemia, and diabetes/pre-diabetes) and the 2 major types of CVDs: atherosclerotic cardiovascular disease (ASCVD) and chronic heart failure. and the China biology medicine, Wanfang, and VIP databases. We also considered published reviews, editorials, and Internet-based sources of information.
THE SEARCH FOR AND SELECTION OF RCTS
Because many RCTs on TCM were published in Chinese, published reports in English or Chinese were included. The search algorithm for MEDLINE was as follows: ("traditional Chinese medicine" OR "TCM") AND ("cardiovascular disease" OR "hypertension" OR "blood pressure" OR "dyslipidemia" OR "hyperlipidemia" OR "lipid" OR "diabetes" OR "pre-diabetes" OR "impaired fasting glucose" OR "impaired glucose tolerance" OR "angina" OR "coronary heart disease" OR "coronary artery disease" OR "myocardial infarction" OR "stroke" OR "heart failure") AND ("randomized" OR "randomized controlled trial") AND "blind,"
with no restriction on subheadings. Similar but adapted search terms were used for other databases of published reports or search engines. The reference lists of all retrieved papers were checked for other potentially relevant citations, and studies not included in the electronic sources mentioned previously were searched manually. Whenever necessary, the authors of the identified papers were contacted for additional information.
We included reports of clinical studies with the following criteria: 1) study patients with a definite diagnosis of essential hypertension, dyslipidemia, diabetes/pre-diabetes, ASCVD, or heart failure who were randomized to receive TCM, contemporary medication, or placebo; 2) sample size in each study group $50 cases; 3) follow-up in each study group $4 weeks; and 4) quantitative measurements of surrogate endpoints and/or adverse cardiovascular events and/or adverse drug effects available to facilitate outcome analysis. We excluded reports of studies with the following features: 1) studies were nonrandomized and/or non-double-blinded; 2) patients enrolled had no definite diagnosis; 3) studies compared different TCM medications; and 4) studies reported only symptomatic changes of patients, without objective laboratory measurements or physical examination. Methodological quality was evaluated for each study with a Jadad score between 0 (weakest) to 5 (strongest), as described previously (6) ; any study with a Jadad score <3 was considered to be of poor quality and was excluded. In addition, when 2 papers reported the results of the same study, the paper with less data was excluded.
Finally, we included 56 eligible reports of RCTs: 21 in English (7-27) and 35 in Chinese Hao et al.
J U N E 2 0 , 2 0 1 7 : 2 9 5 2 -6 6 group B, with evidence from only 1 RCT that had a moderate-quality design (Jadad score: 3 or 4).
TCM FOR RISK FACTORS OF CVD
EFFECT ON HYPERTENSION. Eight RCTs focusing on TCM and essential hypertension were included and assessed (7, 8, (28) (29) (30) (31) (32) (33) . The sample size ranged from 102 to 480 participants, and mean follow-up ranged from 4 to 52 weeks. The methodological quality of the included studies was, in general, high: 7 of 8 reports had a Jadad score of 5 (7, 8, (29) (30) (31) (32) (33) , and 1 RCT on the Bushenheluo formula had a Jadad score of 3 (28) (Online Table 1 EFFECT ON DYSLIPIDEMIA. In the 6 eligible RCTs for treating dyslipidemia with TCM, the following TCM formulations were compared with placebo: Xiaoyujiangzhi capsule, Propolis and ginkgo extract, glossy ganoderma and sea cucumber extract, Jiangzhitongluo capsule, and Salvia miltiorrhiza and Pueraria lobata capsule; Zhibitai capsule was compared with atorvastatin (9, [34] [35] [36] [37] [38] . The sample size ranged from 106 to 288, and the mean follow-up duration was 6 to 52 weeks. The methodological quality of the included studies was, in general, low: only 1 of 6 reports had a Jadad score of 5 (37) , and the other 5 had Jadad scores of 3 or 4 (9,34-36,38) (Online Table 2 ). Table 3 ). A total of 5 RCTs comparing TCM with placebo for pre-diabetes treatment were included and assessed (14, 15, (45) (46) (47) , and the Jadad scores were 5 in 2 RCTs (14,45) and 4 in the other 3 RCTs (15, 46, 47) . The sample size ranged from 122 to 420, and mean followup ranged from 12 to 104 weeks (Online Table 3 ). The sample size ranged from 100 to 4,870, and followup ranged from 4 weeks to 4.5 years (Online Table 4 ).
Data from the high-quality RCTs of TCM interventions
for ASCVD are summarized in the Central Illustration. However, the event rates in both groups were insufficient to generate a firm conclusion (21) . In addition, compared with placebo, Shenzhuguanxin treatment improved angina symptoms, but did not reduce cardiovascular events in patients with CAD (18, 48) .
TCM medications in group B for CAD included the
Xiongshao capsule, Salvia miltiorrhiza and Pueraria Treatment-related adverse events did not differ between these TCM and placebo groups (17, (49) (50) (51) (52) .
Five RCTs comparing TCM with placebo for ischemic stroke were assessed; Jadad scores were 5 in 2 trials (22, 25) and 4 in the other 3 (23, 24, 55) . The sample size ranged from 100 to 1,100, and follow-up ranged from 4 to 104 weeks (Online Table 4 ). 
CENTRAL ILLUSTRATION

TCM FOR CHRONIC HEART FAILURE
We included and assessed 9 RCTs (26,27,56-62) that enrolled 100 to 512 patients with heart failure and had mean follow-ups ranging from 4 to 52 weeks; the Jadad score was 5 in 4 RCTs (26,27,57,59), 4 in 2 RCTs (60,61), and 3 in 3 RCTs (56,58,62) (Online Table 5 ).
The effective response to treatment, defined as an increase of $1 in New York Heart Association (NYHA) functional class, was evaluated in 6 RCTs. There was no significant difference in death or drugrelated side effects between the 2 groups (57). In another RCT with a Jadad score of 3, a cohort of
100 patients with chronic heart failure (mean age 65.9 years) was randomly assigned to receive either Nuanxin capsule or placebo in a 1:1 ratio for 12 months. Nuanxin treatment significantly increased the effective response rate (89.6%) compared with placebo (72.3%), without drug-related side effects (56) . A multicenter RCT enrolling 280 patients with chronic heart failure (mean age 65.6 years) showed that the effective response rate and LVEF were greater with Shencaotongmai than with placebo after 12 weeks of treatment, and the incidence of adverse drug reaction was similar with both treatments (59) . Taken together, these data suggest that some TCM medications, such as Qiliqiangxin, Nuanxin, Shencaotongmai, and Yangxinkang, might be effective in improving cardiac remodeling and function in patients with chronic heart failure, with a good safety profile.
However, the effect of TCM medications on the longterm outcomes of these patients remains obscure. 
POTENTIAL LIMITATIONS OF AVAILABLE RCTS
PHARMACOLOGICAL EFFECTS OF TCM INGREDIENTS ON CVD AND POTENTIAL MECHANISMS
A battery of compounds, including various polyphenols, terpenoids, saponins, and alkaloids (Online Table 6 ), has been isolated from TCMs and shown to have beneficial effects in the cardiovascular system 12. Hu Y, Zhou X, Liu P, Wang B, Duan DM, Guo DH. A comparison study of metformin only therapy and metformin combined with Chinese medicine jianyutangkang therapy in patients with type 2 diabetes: a randomized placebo-controlled
